Patient-centered radiology provider reduces call abandonment by 70%, expands access to 24/7 support and delivers more seamless, empathetic experiences through the Genesys Cloud platform Steinberg Diagnostic
Welcome to your Daily Dose of Health Tech Innovation!Stay ahead with the latest breakthroughs revolutionizing healthcare—from AI diagnostics to remote care solutions.We bring you expert-curated insights,
Polaris AI leverages Google Cloud’s Gemini family of multimodal models and Eleos’ secure and clinically validated infrastructure to reduce documentation burden, strengthen compliance and help
Accord Plasma B.V., a subsidiary of Intas Pharmaceuticals, announced that it has successfully completed the acquisition of Prothya Biosolutions Belgium BV and its subsidiaries. This strategic
PointClickCare, a leading health tech company helping providers deliver exceptional care, announced the limited availability launch of its latest AI-powered innovation, Chart Advisor, alongside the
At HLTH, healthcare’s #1 must-attend innovation event, 51&, a groundbreaking women’s health network, officially launched with a bold mission: to create sustainable, system-wide funding for women’s
Oshi Health, the only nationwide virtual multidisciplinary gastrointestinal (GI) clinic, announced the launch of Access+ for GI practices, a new offering that enables local practices to
Elektra Health, a top virtual menopause care provider, and Oscar Health, Inc, a leading healthcare technology company, announced a groundbreaking partnership offering the first-ever menopause health
Ferring Pharmaceuticals announced the presentation of two real-world data analyses for REBYOTA at IDWeek 2025. These analyses highlight the effectiveness and safety of REBYOTA in
Gilead Sciences, Inc. shared positive data from the Phase 3 ASCENT-03 study demonstrating a highly statistically significant and clinically meaningful improvement in progression-free survival (PFS)
Daiichi Sankyo has announced encouraging early data from the dose escalation phase of its first-in-human Phase 1/2 trial of DS‑3939. The treatment showed promising clinical
Genentech, part of the Roche Group, has reported promising results from its Phase III IMvigor011 trial, evaluating Tecentriq (atezolizumab) as an adjuvant therapy for patients
